Comparative effectiveness research has been the target of recurrent criticism in some political circles, with opponents claiming it’s the “gateway to rationing” or it encourages “cookbook medicine.” ...

Editor’s note: This post is part of a series of several posts related to the 4 th European Forum on Health Policy and Management: Innovation & Implementation, held in Berlin, Germany on January 29 and ...

The complexity of glycemic management in type 2 diabetes mellitus (T2DM) has increased dramatically in the past 15 years. In 1995, the drugs available for treatment of T2DM were insulin and ...

Penny Mohr, MA, senior program officer for improving healthcare systems at the Patient-Centered Outcomes Research Institute, discusses comparative effectiveness research, healthcare disparities, and ...

The main lessons for the United States from the experience of NICE relate to how the institute has gathered, synthesized, and used information on the clinical and cost effectiveness of health care ...

The purpose of comparative effectiveness research (CER) is to provide information that helps clinicians and patients to choose the best treatments for a given individual with a specific medical ...

Ellen-Marie Whelan discusses why we need evidence-based health care, how it will improve health, and how we can promote it. The positions of American Progress, and our policy experts, are independent, ...

A new national initiative in comparative effectiveness research (CER) is part of a broad and long-term evolution toward greater reliance on scientific evidence in clinical practice and medical policy.

On February 17, 2009, President Barack Obama signed into law an initiative providing $1.1 billion to support research on the comparative effectiveness of drugs, medical devices, surgical procedures, ...

With the Patient Protection and Affordable Care Act ("ACA") set to dramatically increase access to medical care, the problem of rising costs will move center stage in health law and policy discussions ...

A research-driven evaluation assessing the comparative effectiveness of phosphodiesterase type 5 (PDE5) inhibitors is contributing to ongoing clinical discourse around vascular-mediated functional ...

John Zalcberg undertook this work while on sabbatical at the National Institute for Clinical Studies but other than in kind support, he did not receive funds from that organisation. The evidence ...